Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-123 in severe sepsis with coagulopathy
2012-002251-42Phase 3Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and severe sepsis comparing ART-123 (thrombomodulin alfa) with Placebo (2 arms). Primary endpoint: Mortality reduction. Started Aug 2012; status: completed.
02
Drugs
thrombomodulin alfa
03
Conditions
sepsissevere sepsis
Beyond the preview
Go deeper on 2012-002251-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002251-42.